Skip to content

A multicenter, prospective cohort study of Tongqiao Biyan granule in the prevention and treatment of asthma allergic rhinitis in children based on the real medical environment and the Chin

A multicenter, prospective cohort study of Tongqiao Biyan granule in the prevention and treatment of asthma allergic rhinitis in children based on the real medical environment and the Chin

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006864
Enrollment
Unknown
Registered
2022-12-13
Start date
2022-12-15
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children's asthma allergic rhinitis

Interventions

Non-exposure group:Standard treatment or combination of allergic rhinitis and western medicine for asthma
Exposure group:Western medicine treatment+Tongqiao rhinitis granule

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 13 Years

Inclusion criteria

Inclusion criteria: (1) having a history of asthma with allergic rhinitis, (2) being 3-13 years old (< 14 years old) , (3) having entered the Chinese childhood asthma action plan and using leisurely breathing APP, being in the Green Zone of asthma, (4) the symptoms of rhinitis (nasal obstruction, nasal discharge, sneezing, nasal itching) appeared recently (nearly 1 week) , or the symptoms of rhinitis aggravated to moderate-severe recently (nearly 1 week) ; (5) voluntary participation in the study and informed consent signed by the legal guardian or with the child (=8 years old) .

Exclusion criteria

Exclusion criteria: (1) having diseases that need to be differentiated from AR, such as upper and lower respiratory tract infection, acute rhinosinusitis, etc. ; (2) having risk factors of fatal asthma attack; (3) being allergic to Tongqiao Biyan granule and its components.

Design outcomes

Primary

MeasureTime frame
Asthma symptom score;Total score of nasal symptoms;

Countries

China

Contacts

Public ContactLi Xinmin
2776026105@qq.com15030202425

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026